Related Experiment Video
Updated: Jun 15, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC
Tingliang Wang1, Yujie Wang2, Jiangrong Lu2
1Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, College of Pharmacy, Guizhou Medical University, Guiyang 561113, China; Department of Pharmacy, Liupanshui Municipal People's Hospital, Liupanshui 553000, China.
Abstract:
Aberrant activation or mutation of the EGFR-PI3K-Akt-mTOR signaling pathway has been implicated in a wide range of human cancers, especially non-small-cell lung cancer (NSCLC). Thus, dual inhibition of EGFR and PI3K has been investigated as a promising strategy to address acquired drug resistance resulting from the use of tyrosine kinase inhibitors. A series of dual EGFR/PI3Kα inhibitors was synthesized using pharmacophore hybridization of the third-generation EGFR inhibitor olmutinib and the PI3Kα selective inhibitor TAK-117. The optimal compound 30k showed potent kinase inhibitory activities with IC50 values of 3.6 and 30.0 nM against EGFRL858R/T790M and PI3Kα, respectively. Compound 30k exhibited a significant antiproliferative effect in NCI-H1975 cells with a higher selectivity profile than olmutinib. The potential antitumor mechanism, molecular binding modes, and in vitro metabolic stability of compound 30k were also clarified.
Insights
Researchers developed a novel dual inhibitor targeting both EGFR and PI3Kα to combat drug resistance in cancers like NSCLC. Compound 30k demonstrated potent activity and selectivity, offering a promising new therapeutic strategy.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Aberrant signaling via the EGFR-PI3K-Akt-mTOR pathway drives various cancers, notably non-small-cell lung cancer (NSCLC).
- Acquired resistance to tyrosine kinase inhibitors (TKIs) necessitates novel therapeutic strategies, such as dual inhibition.
- Targeting both Epidermal Growth Factor Receptor (EGFR) and Phosphoinositide 3-kinase (PI3K) simultaneously presents a promising approach to overcome resistance.
Purpose of the Study:
- To design and synthesize novel dual inhibitors targeting both EGFR and PI3Kα.
- To evaluate the inhibitory potential and antiproliferative effects of the synthesized compounds.
- To elucidate the antitumor mechanism, binding modes, and metabolic stability of the lead compound.
Main Methods:
- Pharmacophore hybridization of olmutinib (EGFR inhibitor) and TAK-117 (PI3Kα inhibitor).
- In vitro kinase inhibition assays to determine IC50 values against EGFR and PI3Kα.
- Antiproliferative assays using NCI-H1975 cells.
- Analysis of antitumor mechanisms, molecular binding, and metabolic stability.
Main Results:
- A series of dual EGFR/PI3Kα inhibitors were synthesized, with compound 30k identified as optimal.
- Compound 30k exhibited potent inhibitory activity: IC50 of 3.6 nM for EGFRL858R/T790M and 30.0 nM for PI3Kα.
- Compound 30k demonstrated significant antiproliferative effects in NCI-H1975 cells with superior selectivity compared to olmutinib.
Conclusions:
- Compound 30k represents a potent dual EGFR/PI3Kα inhibitor with potential for treating resistant NSCLC.
- The study clarifies the antitumor mechanism, binding interactions, and metabolic profile of compound 30k.
- Dual inhibition targeting EGFR and PI3Kα is a viable strategy to overcome acquired drug resistance in cancer therapy.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
